Adjuvant immunochemotherapy in colorectal cancer Dukes C

M. R. Sertoli, D. Guarneri, A. Rubagotti, G. Porcile, M. T. Nobile, R. Rosso

Research output: Contribution to journalArticlepeer-review


The initial aim of the present study was to verify in a randomized trial whether the addition of Levamisole, an immunomodulator, could increase the effectiveness of postoperative chemotherapy (MeCCNU + 5-FU) in Dukes C colorectal cancer patients. After entering 29 consecutive patients, the poor results of most studies of adjuvant therapy in colorectal cancer prompted an early end to patient accrual. After 8 years, the lack of significance in survival (48.9 versus 37.3%) and disease-free survival (50 versus 38.8%) between the two treatment arms rules out any improvement associated with Levamisole administration.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
Issue number2
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Adjuvant immunochemotherapy in colorectal cancer Dukes C'. Together they form a unique fingerprint.

Cite this